首页> 外文期刊>European Journal of Cancer Supplements >Introduction to managing patients with recurrent ovarian cancer
【24h】

Introduction to managing patients with recurrent ovarian cancer

机译:复发性卵巢癌患者管理简介

获取原文
获取原文并翻译 | 示例
           

摘要

Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of death from gynaecological cancer, and is the 4th most common cause of cancer death among UK women. Similar to the majority of other cancers, relative survival rates for ovarian cancer are improving, although 5-year mortality rates remain stubbornly low. The stage of the disease at diagnosis is the single most important determinant of ovarian cancer survival, as many patients first present with advanced disease. Treatment of ovarian cancer involves a combination of 'upfront' primary surgery followed by chemotherapy. Platinum/taxane-based chemotherapy is the recommended standard-of-care first-line chemotherapy, but the majority of patients will relapse with drug-resistant disease within 3-5 years.
机译:卵巢癌是英国女性中排名第五的最常见癌症。它是妇科癌症的主要死亡原因,并且是英国女性中第四大最常见的癌症死亡原因。与大多数其他癌症相似,尽管5年死亡率仍然很低,但卵巢癌的相对生存率正在提高。诊断的疾病阶段是卵巢癌生存的最重要的决定因素,因为许多患者最初都患有晚期疾病。卵巢癌的治疗涉及“前期”基础外科手术后进行化学疗法的组合。铂/紫杉烷类化疗是推荐的护理标准一线化疗,但是大多数患者会在3-5年内复发耐药性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号